We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VCRA
2101
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $695K | ﹤0.01% |
28,000
+1,391
| +5% | +$29.5K |
|
|
SHOE
2102
Shoe Station Group
SHOE
$413M
| $694K | ﹤0.01% |
56,472
+14,056
| +33% | +$180K |
|
|
FTD
2103
DELISTED
FTD Companies, Inc. Common Stock
FTD
| $694K | ﹤0.01% |
34,449
+9,197
| +36% | +$209K |
|
2104
Omeros
OMER
$857M
| $692K | ﹤0.01% |
45,800
+1,258
| +3% | +$13.8K |
|
|
RDUS
2105
DELISTED
Radius Recycling
RDUS
| $692K | ﹤0.01% |
33,517
+530
| +2% | +$12.4K |
|
|
ONIT
2106
Onity Group
ONIT
$309M
| $689K | ﹤0.01% |
8,400
+171
| +2% | +$13K |
|
|
QUOT
2107
DELISTED
Quotient Technology Inc
QUOT
| $689K | ﹤0.01% |
72,111
+3,260
| +5% | +$36K |
|
|
ELGX
2108
DELISTED
Endologix Inc
ELGX
| $689K | ﹤0.01% |
9,520
+289
| +3% | +$19.1K |
|
|
ORBC
2109
DELISTED
ORBCOMM, Inc.
ORBC
| $689K | ﹤0.01% |
72,139
+2,770
| +4% | +$23.8K |
|
2110
AtriCure
ATRC
$1.92B
| $688K | ﹤0.01% |
35,926
+833
| +2% | +$14.6K |
|
|
AMRI
2111
DELISTED
Albany Molecular Research Inc
AMRI
| $688K | ﹤0.01% |
49,046
+12,478
| +34% | +$204K |
|
2112
IDT Corp
IDT
$1.64B
| $687K | ﹤0.01% |
63,828
+16,948
| +36% | +$249K |
|
2113
Casella Waste Systems
CWST
$5.71B
| $686K | ﹤0.01% |
48,632
+1,121
| +2% | +$13.9K |
|
2114
James River Group Holdings
JRVR
$208M
| $686K | ﹤0.01% |
16,001
+587
| +4% | +$24.4K |
|
|
STFC
2115
DELISTED
State Auto Financial Corp
STFC
| $686K | ﹤0.01% |
24,991
+718
| +3% | +$19K |
|
2116
Lexicon Pharmaceuticals
LXRX
$1.03B
| $682K | ﹤0.01% |
47,526
+1,281
| +3% | +$19K |
|
2117
Valvoline
VVV
$4.9B
| $682K | ﹤0.01% |
27,783
+5,187
| +23% | +$119K |
|
2118
Dime Commercial Bancshares
DCOM
$1.8B
| $681K | ﹤0.01% |
19,465
+1,239
| +7% | +$44.4K |
|
2119
Gogo Inc
GOGO
$565M
| $681K | ﹤0.01% |
61,867
+1,687
| +3% | +$17K |
|
|
ITCI
2120
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $680K | ﹤0.01% |
41,841
+1,445
| +4% | +$20.9K |
|
|
AXDX
2121
DELISTED
Accelerate Diagnostics
AXDX
| $679K | ﹤0.01% |
2,808
+86
| +3% | +$19.6K |
|
2122
PJT Partners
PJT
$4.35B
| $679K | ﹤0.01% |
19,337
+721
| +4% | +$25K |
|
|
ESPR
2123
DELISTED
Esperion Therapeutics
ESPR
| $677K | ﹤0.01% |
19,180
+2,846
| +17% | +$65.2K |
|
2124
MacroGenics
MGNX
$235M
| $676K | ﹤0.01% |
36,350
+222
| +0.6% | +$4.28K |
|
2125
Federal Agricultural Mortgage
AGM
$2.47B
| $673K | ﹤0.01% |
11,694
+284
| +2% | +$16.4K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.